NRGENE TECHNOLOGIES LTD (IL:NRGN)
TASE:NRGN
Top Page
Nrgene
(TASE:NRGN)
Select Model
Select Model
Rating:40Underperform
Price Target:
217.00
▲(5.96% Upside)
Action:DowngradedDate:12/31/25
The score is driven primarily by weak financial performance (declining revenue, ongoing losses, and negative operating/free cash flow), reinforced by bearish technical signals (below major moving averages and negative MACD). Valuation provides limited support due to the negative P/E and lack of a dividend yield.
Positive Factors
Proprietary IP
Nrgene's proprietary algorithms and genomic tools provide durable differentiation and technical barriers. This IP supports licensing, bespoke services and deeper integration with partner pipelines, enabling recurring fees and higher switching costs that sustain competitive advantage over months.
Negative Factors
Steep Revenue Decline
A multi-year drop from $7.6M to $1.29M materially reduces scale and operating leverage. Lower top-line volumes weaken pricing power and margins, constrain R&D and sales investment, and make it difficult to rebuild commercial momentum without new products or sizable new contracts.
Read all positive and negative factors
Positive Factors
Negative Factors
Proprietary IP
Nrgene's proprietary algorithms and genomic tools provide durable differentiation and technical barriers. This IP supports licensing, bespoke services and deeper integration with partner pipelines, enabling recurring fees and higher switching costs that sustain competitive advantage over months.
Read all positive factors
Nrgene (NRGN) vs. iShares MSCI Israel ETF (EIS)
Market Cap
₪35.95M
Dividend YieldN/A
Average Volume (3M)27.56K
Price to Earnings (P/E)―
Beta (1Y)0.55
Revenue Growth-23.68%
EPS Growth31.97%
CountryIL
Employees29
SectorTechnology
Sector Strength88
IndustrySoftware - Application
Share Statistics
EPS (TTM)-52.50
Shares Outstanding13,313,626
10 Day Avg. Volume57,803
30 Day Avg. Volume27,561
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)2.10
Price to Sales (P/S)6.44
P/FCF Ratio-1.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Nrgene Business Overview & Revenue Model
Company Description
NRGene Technologies Ltd, an AI genomics company, provides computational tools and develops advanced algorithms in North America, Europe, Middle East, Africa, Asia Pacific, and internationally. It offers software tools; and turnkey solutions to bre...
How the Company Makes Money
Nrgene generates revenue through a diversified model that includes service contracts for genomic analysis, licensing of its proprietary software and algorithms, and partnerships with agricultural companies and research institutions. The company of...
Nrgene Financial Statement Overview
Summary
Income Statement
30
Negative
Balance Sheet
40
Negative
Cash Flow
35
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 902.00K | 1.29M | 2.00M | 3.16M | 4.46M | 7.04M |
| Gross Profit | 59.00K | 267.00K | 901.00K | 1.71M | 2.46M | 4.51M |
| EBITDA | -1.89M | -2.69M | -4.53M | -5.59M | -8.37M | -1.75M |
| Net Income | -2.34M | -3.36M | -5.24M | -6.21M | -8.34M | -3.15M |
Balance Sheet | ||||||
| Total Assets | 6.10M | 6.00M | 10.79M | 17.30M | 26.36M | 3.80M |
| Cash, Cash Equivalents and Short-Term Investments | 1.96M | 1.37M | 6.45M | 12.28M | 22.87M | 1.48M |
| Total Debt | 150.00K | 288.00K | 797.00K | 1.61M | 3.34M | 5.08M |
| Total Liabilities | 3.72M | 2.00M | 3.57M | 5.04M | 8.68M | 9.33M |
| Stockholders Equity | 2.35M | 3.96M | 7.21M | 12.26M | 17.68M | -5.53M |
Cash Flow | ||||||
| Free Cash Flow | -3.24M | -5.19M | -5.58M | -7.83M | -6.67M | -1.44M |
| Operating Cash Flow | -1.67M | -3.56M | -3.91M | -6.12M | -5.57M | -1.42M |
| Investing Cash Flow | -208.50K | -1.30M | -1.27M | 12.47M | -14.83M | -33.00K |
| Financing Cash Flow | 663.50K | -317.00K | -410.00K | -2.46M | 27.59M | 326.00K |
Nrgene Technical Analysis
Positive
204.80
Price Trends
228.32
Positive
251.70
Negative
Market Momentum
4.23
Negative
71.57
Negative
99.75
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IL:NRGN, the sentiment is Positive. The current price of 204.8 is below the 20-day moving average (MA) of 231.63, below the 50-day MA of 228.32, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of 4.23 indicates Negative momentum. The RSI at 71.57 is Negative, neither overbought nor oversold. The STOCH value of 99.75 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IL:NRGN.
Nrgene Peers Comparison
UnderperformOutperform
Sector (61)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
67 Neutral | ₪4.42B | 24.02 | ― | 2.55% | 14.11% | 25.79% | |
62 Neutral | ₪8.12B | 28.90 | ― | 2.41% | 8.82% | 14.25% | |
61 Neutral | $37.18B | 12.37 | -10.20% | 1.83% | 8.50% | -7.62% | |
60 Neutral | ₪444.22M | 40.14 | ― | ― | 19.46% | -27.35% | |
42 Neutral | ₪56.53M | -3.41 | ― | ― | 14.39% | -1797.14% | |
40 Underperform | ₪35.95M | -2.78 | ― | ― | -23.68% | 31.97% |
* Technology Sector Average
IL:NRGN
Nrgene
270.00
-20.00
-6.90%
IL:ABRA
Abra
379.40
72.10
23.46%
IL:SNEL
Synel
1,808.00
178.83
10.98%
IL:ONE
One Technologi
6,001.00
-667.87
-10.01%
IL:MTRX
Matrix
8,774.00
118.80
1.37%
IL:PHTM
Photomyne
2,100.00
-980.00
-31.82%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.